Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Maurice Markus (NPI 1073590782)

Field	Value
Entity Type	Individual
Organization	Maurice Markus
Address	2312 N Nevada Ave Ste 400
City	Colorado Springs
State	CO
ZIP	80907
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 23, 2005

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician with a long NPI tenure, enumerated on 2005-12-23 (~21 years ago), indicating established practice presence in Colorado Springs and likely sustained clinical operations over two decades. The long enrollment period supports experience administering oncology treatments and related diagnostics reflected in the billing mix.

Medicare is effectively the sole public payer on file for this provider: Total Medicare revenue is listed as $1.6M while there is no Medicaid billing on file, indicating a single-payer footprint in available public claims data and limited exposure to state Medicaid populations. This concentration suggests payer strategy, contracting, and patient mix will be dominated by Medicare beneficiaries.

Revenue concentration is high in a small number of drug administration codes: the top 3 Medicare codes by revenue account for 69.8% of the provider’s total Medicare revenue, with J9271 alone contributing $614.9K (39.8% of Medicare revenue). This indicates the practice’s financial reliance on high-cost oncology injectables and immunotherapies rather than clinic visit E/M or ancillary testing.

The code mix and descriptions show an infusion- and injectable-heavy oncology practice: leading codes J9271 (pembrolizumab), J9299 (nivolumab), and J9144 (daratumumab with hyaluronidase) are high-cost biologic agents administered in clinic, and additional administration codes (96413, 96365, 96367, 96417) and chemotherapy administration G0498 appear in the top codes. These items together imply the operation centers on infusion services, oncology drug management, and PET/CT diagnostic imaging support.

Competitive standing for the top drug codes is modest to typical nationally: J9271 ranks #739 of 1841 providers (60th percentile) and is described as typical, unremarkable volume; J9299 ranks #310 of 505 providers (39th percentile) and J9144 ranks #500 of 615 providers (17th percentile). Those percentiles indicate the provider is not a national leader for these agents but maintains routine, serviceable volume consistent with an established oncology infusion practice.

There are several service lines beyond drug administration that contribute meaningfully to revenue and clinical workflow: imaging and diagnostics such as A9595 ($111.6K, Piflufolastat f-18) and 78815 (PET/CT, $100.4K) appear in the top codes, reflecting integration of advanced diagnostic imaging into care pathways. This combination of high-cost therapeutics and diagnostic imaging suggests comprehensive oncology care rather than isolated consult-only practice.

Evaluation-and-management visits and routine labs appear in lower revenue positions but with relatively high claim counts—e.g., 99214 (477 claims, $44.8K) and 99213 (503 claims, $30.7K), plus CBC and CMP codes (85025, 80053) and specimen collection (36415). These patterns indicate steady ambulatory follow-up and in-clinic support services that accompany the infusion-heavy business model.

Several codes are characterized as typical, unremarkable volume on national benchmarks even when claim counts are high (for example, 99214 at the 89th percentile for visit volume is still labeled “typical, unremarkable volume”). Overall, the provider’s rankings cluster in percentiles that point to a stable, moderately busy oncology practice rather than a regional or national outlier in utilization intensity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	14,300	$40	$614.9K
J9299	Injection, nivolumab, 1 mg	11,680	$20	$280.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,860	$40	$184.7K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	240	$470	$111.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,220	$100.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	480	$90	$44.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	330	$110	$35.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	500	$60	$30.7K
J0897	Injection, denosumab, 1 mg	1,440	$20	$25.9K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	110	$130	$14.9K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Maurice Markus — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	40	10,700	$40	$520.5K
J9299	2	10	10,930	$20	$355.1K
J9144	24	20	7,560	$40	$354.8K
A9595	9	20	220	$540	$141.1K
J0897	110	140	2,580	$20	$68.8K
78815	43	120	60	$540	$58.9K
J0881	10	10	7,670	$1	$23.4K
J3490	34	60	50	$290	$23.1K
96413	27	140	130	$100	$19.7K
J9217	19	60	100	$130	$15.6K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Maurice Markus, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Maurice Markus, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
A Physicians Home Care	CO	In Home Supportive Care Agency	$0	$247.9M
A Circle Of Care Colorado, LLC.	CO	In Home Supportive Care Agency	$0	$101.8M
Goodwill Of Colorado	CO	Home Health Agency	$0	$33.3M
Stellar Care And Services, LLC	CO	Child Intellectual and/or Developmental Disabilities Respite Care	$0	$31M
Catholic Health Initiatives Colorado	CO	General Acute Care Hospital	$0	$25.2M
American Medical Response Of Colorado Inc	CO	Ambulance	$3.4M	$21.6M
Special Kids Special Families	CO	Developmentally Disabled Services Day Training Agency	$0	$24.8M
Lucas Inc	CO	Respite Care	$0	$23.6M
Achieve Whole Recovery, PC	CO	Specialist	$0	$22.7M
Loving Care Agency, Inc.	CO	In Home Supportive Care Agency	$0	$18.2M

Maurice Markus — Billing Profile & Reimbursement Data

Sign up for Maurice Markus — Billing Profile & Reimbursement Data policy alerts

Maurice Markus — Billing Profile & Reimbursement Data

Sign up for Maurice Markus — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References